Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review

César David Galindo-Calvillo 1, Carlos Saúl Rodríguez-Roque 1, Andrés Gómez-De León, Luz Tarín-Arzaga, David Gómez-Almaguer

Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

A R T I C L E   I N F O

Keywords:
Thrombotic thrombocytopenic purpura
Monoclonal antibodies
Rituximab
Plasma exchange
Caplacizumab

A B S T R A C T

We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be unnecessary for a subset of patients with relapsed TTP who are clinically stable without significant end-organ damage. A brief literature review regarding TTP patients treated without plasma exchange is also included.

1. Introduction

There are two main types of thrombotic thrombocytopenic purpura (TTP): congenital and acquired, with the latter being the most common. Congenital TTP is caused by a deficiency of metalloprotease thrombospondin type 1 motif 13 (ADAMTS13), which has a proteolytic activity towards von Willebrand factor (VWF). In its acquired immune-mediated form, autoantibodies inhibit the cleaving activity of ADAMTS13 triggering ultra-large VWF multimers that circulate freely and spontaneously bind to platelets. These multimers cause microangiopathic hemolytic anemia (MAHA) that results in tissue ischemia, end-organ damage, thrombocytopenia, and therefore, risk of bleeding. Diagnosis is made by combining clinical and laboratory features. The most common laboratory findings are thrombocytopenia and microangiopathic hemolytic anemia, schistocytes in the peripheral blood smear, a high reticulocyte count, elevated lactate dehydrogenase (LDH), and low haptoglobin. Creatinine levels might be elevated, and proteinuria or hematuria may be present if kidney injury occurs. The diagnosis of immune-mediated TTP is confirmed with a reduced plasma ADAMTS-13 activity (<10 %) in the presence of ADAMTS-13 antibodies [1]. The clinical findings include pallor, petechiae, fatigue, and neurological symptoms, among others [2]. Plasma exchange (PEx) in addition to corticosteroids are first-line treatment. Rituximab has been included as adjuvant therapy in both first-line therapy or relapsed disease [3]. In this report, we present the case of a patient diagnosed with a TTP relapse, treated exclusively with prednisone and low-dose rituximab during the COVID-19 pandemic, we also performed a brief literature review on this topic.

2. Case presentation

A previously healthy 20-year-old woman was diagnosed with immune-mediated TTP, after presenting with MAHA, kidney injury, and neurological symptoms. She was treated with eight PEx sessions. One year later, she relapsed and underwent splenectomy, gaining a complete response, and remained in yearly clinical surveillance without further relapses. Ten years after the first relapse, she presented with a headache, nausea, and disseminated ecchymoses on both legs. She was stable with an otherwise unremarkable physical examination. No triggering factors such as infection, pregnancy, alcohol, or drug use were detected. Baseline laboratory findings are shown in Table 1. Elevated reticulocytes (15.5 %) and schistocytes were observed in the blood smear. Creatinine and troponins were normal. ADAMTS13 activity was not detected, and the ADAMTS13 IgG antibody level was 25.51 U/mL (positive activity threshold of >15 U/mL) confirming a second relapse of acquired immune-mediated TTP without clinically apparent end organ-damage.

https://doi.org/10.1016/j.transci.2021.103107
Received 3 February 2021; Received in revised form 22 February 2021; Accepted 25 February 2021
Available online 27 February 2021
1473-0502/© 2021 Elsevier Ltd. All rights reserved.
**Table 1**

| Hemoglobin (g/dL) | Leukocytes (x10^3/L) | Platelets (x10^9/L) | LDH (UI/L) |
|------------------|----------------------|---------------------|-------------|
| **Baseline**     | 8.7                  | 23.1                | 28          | 988         |
| **Day 7**        | 9                    | 22                  | 30          | 938         |
| **Day 14**       | 7.8                  | 17.5                | 47          | –           |
| **Day 21**       | 10.1                 | 14.3                | 195         | –           |
| **Day 28**       | 11                   | 8.89                | 462         | 251         |
| **Day 42**       | 13                   | 12                  | 420         | –           |
| **Day 80**       | 13                   | 12.5                | 400         | 182         |
| **Day 215**      |                      | 350                 | 133         | –           |

LDH, lactic dehydrogenase.

*LDH upper limit of normal: 180 UI/L.

Considering the absence of neurological symptoms and the lack of resources, brain imaging was omitted. We recommended she be immediately hospitalized to receive PEx and corticosteroids. However, due to the lack of availability during the current COVID-19 pandemic, facing significant bureaucratic economical, insurance-related issues, and lacking available beds, PEx was not a viable option. After a detailed explanation considering the lack of PEx, the patient gave her informed consent for an alternative therapy. Consequently, a therapy with prednisone and rituximab was chosen. The schema consisted of rituximab 100 mg weekly for 4 doses in combination with prednisone 1 mg/kg PO [4]. The patient had clinical improvement after her first rituximab administration with symptom resolution but persisted with laboratory parameters compatible with MAHA (Table 1); elevated schistocytes, LDH 938 UI/L, and an indirect bilirubin level of 1.7 mg/dL. She remained clinically stable and completed 4 doses of rituximab without complications. Her laboratory findings revealed hemoglobin 11 g/dL, platelets 462,000/μL, and LDH 251 IU/L. Prednisone was tapered over 4 weeks. She remained asymptomatic, and laboratory findings showed a complete response at day 42 (Fig. 1) including a small increase in ADAMTS13 activity. The patient is currently living a normal life without PEx and undergoing clinical surveillance without anemia, thrombocytopenia, hemolysis (bilirubin and LDH in normal range), or renal injury (serum creatinine 0.6 mg/dL). Remarkably, the latest ADAMTS13 activity level at the 6-month follow-up visit showed 3% activity (range 3–68%), the IgG anti-ADAMTS13 level was 77.35 U/mL (positive activity threshold is >15U/mL), with no sign of anemia, thrombocytopenia, or acute hemolysis. She is currently receiving pre-emptive rituximab.

3. **Discussion**

TTP treatment is based on counteracting the microthrombotic stimulus and acute end-organ damage to avoid the high mortality associated with untreated disease. The frontline approach includes PEx which replenishes functional ADAMTS13 and removes von Willebrand factor and its autoantibodies, combined with immunosuppressive therapy to counter ADAMTS13 antibody activity [3]. In this case, the unavailability of PEx or plasma infusions to treat a clinical TTP relapse represented a clinical challenge. Leukocytes were elevated at baseline without infection and were attributed to the splenectomy history as no trigger was documented. The patient was treated safely with rituximab and prednisone only, and to our knowledge, represents the first case treated with this management strategy. She did not experience significant adverse events and obtained a complete response. Recently a case of severe TTP was reported, in which the patient achieved complete remission after therapy with steroids plus rituximab but without PEx. However, it is important to note that plasma extraction was performed and replaced with human albumin solution [5]. Similar cases of TTP in Jehovah’s Witnesses treated without PEx using corticosteroids, rituximab, and albumin as a replacement fluid in combination with different drugs have also been reported (Table 2) [5–12]. In this scenario, it is difficult to evaluate the contribution of plasma extraction or fluid replacement alone versus the use of rituximab and corticosteroids on the good response obtained by those patients.

Corticosteroids are considered a useful standard adjunct to PEx [3]. It was recognized as beneficial for patients even before PEx emerged as the standard of care, but currently, it is uncertain if an additional benefit is obtained by adding steroids to PEx [13]. Rituximab is frequently utilized as a first-line or relapsed disease adjuvant, usually at a dose of 375 mg/m² administrated for 4 weeks, resulting in an 83–100% complete remission rate [14,15] potentially decreasing the time to response and delaying subsequent relapses [16]. Also, its pre-emptive use in asymptomatic patients who experience a drop in ADAMTS13 levels has emerged as a promising strategy [17]. We and other authors have previously shown that low-dose rituximab (100 mg weekly) has been an efficacious adjuvant therapy for patients in acute episodes [4,18,19] and our initial observations were recently confirmed [20]. Low-dose rituximab has also been used in other hematological immune-mediated disorders, being a natural addition to patients with TTP [18,21]. Rituximab efficiently depletes B-cells in TTP patients in 24 h, decreasing plasma levels of ADAMTS13 antibody activity and improving immune tolerance.
ADAMTS13 inhibitor levels [22]. Therefore, this capacity could partly explain the good clinical response observed in our patient. Her clinical presentation was not severe, probably the most important factor associated with a favorable response to immunosuppressive therapy alone. Our patient had previously undergone splenectomy, nonetheless, relapses occur in about 35 % of splenectomized patients [23]. It is unclear whether she was favorably affected by this procedure, as the role of the spleen in TTP pathogenesis is still a matter of debate. It is the major source of autoantibody production and antibody-antigen complex clearance and its removal may decrease the risk of relapse [24].

Caplacizumab, a humanized nano-body that targets the A1 domain of von Willebrand factor, preventing interaction with the platelet glycoprotein Ib-IX-V receptor, is a novel treatment used in combination with PEx. This therapy has been shown to achieve earlier responses, fewer PEx sessions, and fewer relapses compared to placebo [25]. However, it is not available in our country and is highly expensive. Furthermore, it has been recently reported in a German retrospective study that patients could be treated with caplacizumab without PEx depending on their clinical presentation and evolution, rapidly reestablishing platelet levels and achieving clinical responses [26]. Moreover, a Jehovah’s Witness patient with severe TTP received prednisone, rituximab, caplacizumab, and factor VIII, without PEx or plasma extraction and recovered rapidly [12]. Nevertheless, the cost of this drug is a limiting factor for low-middle income countries, such as Mexico.

In our patient, ADAMTS13 activity remains low, therefore a congenital TTP should be considered. Congenital TTP usually presents during early infancy, or late infancy with life-threatening thrombosis, although some patients can remain asymptomatic for decades until a triggering factor appears, usually leading to organ damage [29]. It is difficult to differentiate an acquired TTP from an inherited TTP; however, the presence of ADAMTS13 antibodies, the absence of renal and brain damage, and the absence of a triggering factor suggest acquired TTP [30]. Our patient recently tested positive for ADAMTS13 antibodies; interestingly, she has not presented clinical exacerbation or new symptoms. Also, this laboratory finding helped to ensure the acquired form of TTP. Moreover, the ADAMTS13 activity level fluctuation has been reported in the follow-up of asymptomatic TTP patients. In some cases, this represents a predictor of relapse [31].

4. Conclusion

To the best of our knowledge, this is the first patient that has been treated with corticosteroids plus low dose rituximab without PEx. Can we identify a subset of patients with TTP that can be treated without PEx successfully? Only a handful of patients have been successfully treated without plasma exchange. Since this is a single case experience, reporting bias cannot be excluded and therefore, our findings must be interpreted cautiously. The patient is asymptomatic but still undergoing treatment due to the low levels of ADAMTS-13. We acknowledge that PEx is the current gold standard in the treatment of TTP. However, our approach could be another effective method to handle specific presentations in selected uncomplicated patients suffering from TTP relapses in similar settings.

CRediT authorship contribution statement

César David Galindo-Calvillo: Writing - original draft, Methodology, Investigation, Writing - review & editing. Carlos Suád Rodríguez-Roque: Writing - original draft, Methodology, Investigation, Writing - review & editing. Andrés Gómez-De León: Supervision, Visualization. Luz Tarín-Araga: Supervision, Writing - review & editing. David Gómez-Almaguer: Conceptualization, Visualization, Project administration, Validation.

Declaration of Competing Interest

The authors declare that they have no conflicts of interests.

Acknowledgements

We thank Sergio Lozano-Rodríguez, MD for critically reading our manuscript and suggesting substantial improvements.

References

[1] Joly Bérangère S, Paul Coppo AV. Thrombotic thrombocytopenic purpura. Blood 2017;129. https://doi.org/10.1016/j.dIssmon.2014.08.005. 2863-46.
[2] Chiasakul T, Gurer A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Prog 2018;2018:530-8. https://doi.org/10.1182/asheducation.2018.1.530.
[3] Gómez-De León A, Villela-Martínez LM, Vázquez-Ruiz JM, Gómez-Almaguer D. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. Expert Rev Hematol 2020;13:461-70. https://doi.org/10.1080/17474086.2020.1750361.
[4] Bugarin-Estrade E, Gómez-De León A, López-García YK, Díaz-Chue EA, Priesca-Marin JM, Ruiz-Artiguelles GJ, et al. Clinical presentation in thrombotic thrombocytopenic purpura: real-world data from two Mexican institutions. J Clin Apher 2018;33:645-53. https://doi.org/10.1002/jca.21659.
[5] Baseri B, Vishwathanan S, Banasher D, Khazaan M, Luhrs C, Tsai H. Survival of a Jehovah’s Witness with thrombotic thrombocytopenic purpura without using plasma: a case report and review of the literature. J Clin Apher 2019;34:623-30. https://doi.org/10.1002/jca.21710.
[6] Dabak V, Kuriakose P, Raman S. Successful management of a Jehovah’s Witness with thrombotic thrombocytopenic purpura unwilling to be treated with plasma: a case report and review of the literature. J Clin Apher 2019;34:623-30. https://doi.org/10.1002/jca.21710.
[7] Chai W, Chadary A, Robinowitz AP. Successful management of thrombotic thrombocytopenic purpura in a Jehovah’s Witness without plasma exchange. J Clin Apher 2015;30:46-9. https://doi.org/10.1177/jca.21325.
[8] Sam C, Desai P, Laber D, Patel A, Viswanath N, Jaglal M. Peggadity bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med 2017;27:300-2. https://doi.org/10.1111/tme.12407.
[9] George JN, Sandler SA, Stankiewicz J. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience. Blood Adv 2017;1:2161-4. https://doi.org/10.1182/bloodadvances.2017012351.
[10] Drummond MW, Green R, Callaghan T, Watson D, Simpson K, Unit CA, et al. Letter to the editor Management of a Jehovah’s witness with thrombotic thrombocytopenic Purpura / haemolytic uraemic syndrome. J Clin Apher 2000; 206-267.
[11] Lim My, Greenberg Cs. Successful management of thrombotic thrombocytopenic Purpura in a Jehovah’s witness: an individualized approach with joint decision-making. J Patient Exp 2020;7:8-11. https://doi.org/10.1177/2371373519829902.
[12] Chander D, Loch M. Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic Purpura. SC-NEJ, 2019. https://doi.org/10.1056/NEJMoa1905426.

[13] Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic Purpura-Hemolytic Uremic syndrome. N Engl J Med 1991;325:398–403. https://doi.org/10.1056/NEJM199106083250605.

[14] Jasti S, Coyle T, Gentile T, Rosales I, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23:151–6. https://doi.org/10.1002/jca.20172.

[15] Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 2016;127:3092–4. https://doi.org/10.1182/blood-2016-03-703827.

[16] Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 2015;125:1526–31. https://doi.org/10.1182/blood-2014-10-559211.

[17] Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology 2018;2018:539–47.

[18] Vázquez-Mellado A, Pequeño-Luévano M, Cantu-Rodríguez OG, Villarreal-Martínez L, Jaime-Pérez JC, Gómez-De-León A, et al. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematology 2016;21:311–6.

[19] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7. https://doi.org/10.1111/jth.14768.

[20] Zwicker JI, Mula J, Dolatshahi L, Westfield LA, Neters P, Rodrigues A, et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood 2019;134:1106–9. https://doi.org/10.1182/blood.201900795.

[21] Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Celballos-López AA, Ruiz-Aruguelles GJ, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as front-line therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013;90:494–500. https://doi.org/10.1111/ejh.12102.

[22] Carden MA, Gadd M, Hasko K, Brown M, Merrill V, Stowell SR, et al. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv 2020;4:477–81. https://doi.org/10.1182/bloodadvances.2019001148.

[23] Sys J, Provan D, Schaauwvlieghen A, Vanderschueren S, Dierickx D. The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering? Blood Rev 2017;31:159–72. https://doi.org/10.1016/j.blre.2017.03.001.

[24] Dubois L, Gray DK. Splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg 2010;53:349–55.

[25] Scully M, Cataland SR, Peyvandi F, Cuppo P, Knobl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380:335–46. https://doi.org/10.1056/NEJMoa1806311.

[26] Volker LA, Kaufeld J, Miesbach W, Brahler S, Reinhardt M, Kühne L, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 2020;4:3085–92. https://doi.org/10.1182/bloodadvances.2020001973.

[27] Hasenpflug WA, Budde U, Schneppenheim S, Schneppenheim R. Inherited thrombotic thrombocytopenic purpura. Semin Thorb Haemost 2014;40:487–92. https://doi.org/10.1055/s-0034-1376152.

[28] Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic Purpura. N Engl J Med 2019;381:1653–62. https://doi.org/10.1056/nejmoa1813013.

[29] Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008;141:651–8. https://doi.org/10.1111/j.1365-2141.2008.07107.x.